Dianthus Therapeutics Inc... (DNTH)
NASDAQ: DNTH
· Real-Time Price · USD
36.26
0.42 (1.17%)
At close: Sep 26, 2025, 11:05 AM
1.17% (1D)
| Bid | 36.13 |
| Market Cap | 1.17B |
| Revenue (ttm) | 4.85M |
| Net Income (ttm) | -114.75M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -11.51 |
| Forward PE | -10.48 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 36.37 |
| Volume | 65,201 |
| Avg. Volume (20D) | 605,526 |
| Open | 36.02 |
| Previous Close | 35.84 |
| Day's Range | 35.79 - 37.63 |
| 52-Week Range | 13.37 - 39.87 |
| Beta | 1.00 |
| Ex-Dividend Date | n/a |
About DNTH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DNTH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DNTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsDianthus Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+11.86%
Dianthus Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
2 weeks ago
+20%
DNTH stock has given up its prior loss. Dianthus Therapeutics shares were trading lower. The company announced top-line data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized Myasthenia Gravis.
